Evidence map›Paper›PMID 33620621›Full record

SynthesisHeart failure reviews2022

SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis.

Mahmoud Barbarawi, Ahmad Al-Abdouh, Owais Barbarawi, Harini Lakshman, Mariam Al Kasasbeh, Kai Chen

Abstract readMeta-AnalysisReview
PubMed Publisher
In one paragraph

Synthesis in Heart failure reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Observational
  8. Review
  9. Myeloproliferative Neoplasms and Sodium-Glucose Co-Transporter-2 Inhibitors: A Case SeriesTurkish journal of haematology : official journal of Turkish Society of Haematology · 2024
    Article
  10. Review
  11. Review
  12. Article
  13. Diabetic kidney disease in children and adolescents: an update.Pediatric nephrology (Berlin, Germany) · 2022
    Review
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Mahmoud BarbarawiDepartment of Cardiology, University of Connecticut, Farmington, CT, USA. Mahmoud.albarbarawi@gmail.com.ORCID 0000-0001-8218-2466
Ahmad Al-AbdouhDepartment of Internal Medicine, Saint Agnes Hospital, Baltimore, MD, USA.
Owais BarbarawiDepartment of Internal Medicine, Mutah University, Al-Karak, Jordan.
Harini LakshmanDepartment of Internal Medicine, Hurley Medical Center, Michigan State University, Flint, MI, USA.
Mariam Al KasasbehDepartment of Health Administration, Western Connecticut State University, Danbury, CT, USA.
Kai ChenDepartment of Cardiology, University of Connecticut, Farmington, CT, USA.
University of Connecticut · USHurley Medical Center · USMutah University · JOSaint Agnes Hospital · USWestern Connecticut State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events and renal outcomes in patients with diabetes mellitus (DM). This meta-analysis aimed to provide a thorough evaluation regarding the efficacy and safety of SGLT2 inhibitors. Data search of MEDLINE/PubMed, Embase, and Cochrane Library databases and ClinicalTrials.com from inception through November 26, 2020. We included randomized trials, SGLT2 inhibitors compared with placebo, patients with or without diabetes at recruitment, and reporting the incidence of cardiovascular or renal outcomes. Two authors extracted pertinent data into predefined data collection tables. Ten trials were included (71,553 patients). The mean age was 64.7 ± 8.4 years, with 65.1% male. Follow-up durations range 9-50 months. Inhibition of SGLT2 resulted in lower composite outcome of heart failure (HF) hospitalization or cardiovascular death (RR 0.76, 95% CI 0.73-0.81, P < 0.01) and lower risk of renal outcomes (RR 0.68, 95% CI 0.60-0.77, P < 0.01). Furthermore, SGLT2 inhibitors were associated with lower major adverse cardiovascular events (MACEs), HF hospitalization, cardiovascular mortality, all-cause mortality, myocardial infarction, and serious adverse events, compared with placebo (P < 0.05). Sensitivity analyses revealed lower MACE events also in patients with HF, and a lower HF hospitalization and cardiovascular mortality in non-diabetic patients (P < 0.05). While the amputation risk was comparable between the two groups, the risk of diabetic ketoacidosis was higher in the SGLT2 inhibitor group. Inhibition of SGLT2 in patients with DM and prevalent ASCVD reduces the risk of HF hospitalization, cardiovascular mortality, all-cause mortality, MACE, and renal outcomes without increasing the risk of serious adverse events or amputation.

Indexed as

Cardiovascular DiseasesCardiovascular SystemDiabetes Mellitus, Type 2Myocardial InfarctionSodium-Glucose Transporter 2 InhibitorsAgedFemaleHumansMaleMiddle AgedSodium-Glucose Transporter 2Sodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsCardiovascular diseaseDiabetesMeta-analysisRenal diseaseSGLT2 inhibitor

Identifiers

PMID33620621
OpenAlexW3131749016

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.